Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference60 articles.
1. TOR signaling in growth and metabolism;Wullschleger;Cell,2006
2. The TOR pathway: a target for cancer chemotherapy;Bjornsti;Nat Rev Cancer,2004
3. Optimal targeting of the mTORC1 kinase in human cancer;Lane;Curr Opin Cell Biol,2009
4. Targeting the mTOR signaling network for cancer therapy;Meric-Bernstam;J Clin Oncol,2009
5. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises;Yap;Curr Opin Pharmacol,2008
Cited by 114 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Autophagy modulation in cancer therapy: Challenges coexist with opportunities;European Journal of Medicinal Chemistry;2024-10
2. The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features;The Journal of Pathology: Clinical Research;2024-04-02
3. From carcinogenesis to therapeutic avenues: lncRNAs and mTOR crosstalk in lung cancer;Pathology - Research and Practice;2024-01
4. Head and neck cancer stem cell maintenance relies on mTOR signaling, specifically involving the mechanistic target of rapamycin complexes 1 and 2 (mTORC1 and mTORC2);Archives of Oral Biology;2024-01
5. Updates on altered signaling pathways in tumor drug resistance;Visualized Cancer Medicine;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3